AKORN, INC. SIGNS A DEFINITIVE PURCHASE AND SUPPLY AGREEMENT WITH NATCO PHARMA

Akorn today announced that it has signed a Purchase and Supply Agreement with Natco Pharma Limited, located in Hyderabad, India, to commercialize two ANDA oral drug products for cancer patients suffering from nausea and vomiting. The two drug products will focus on the anti-emetic market, and have a current market size of approximately $800 million. Natco will be responsible for the development and manufacturing of both drug products, while Akorn will be responsible for marketing and distribution in the hospital, clinic, and home healthcare markets in the United States and Canada.
Business Wire